Analysts Expect Stemline Therapeutics to Announce ($0.60) Earnings Per Share (NASDAQ:STML)

Shares of Stemline Therapeutics (NASDAQ:STML) have received an average broker rating score of 1.00 (Hold) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus price target of $51.25 for the company and are predicting that the company will post ($0.60) earnings per share for the current quarter, according to Zacks. Zacks has also given Stemline Therapeutics an industry rank of 47 out of 265 based on the ratings given to its competitors.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at 17.06 on Friday. Stemline Therapeutics has a 52 week low of $10.50 and a 52 week high of $31.48. The stock has a 50-day moving average of $15.21 and a 200-day moving average of $13.51. The company’s market cap is $221.1 million.

Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.05. During the same quarter in the previous year, the company posted ($0.45) earnings per share. Analysts expect that Stemline Therapeutics will post $-2.30 EPS for the current fiscal year.

A number of research firms have recently commented on STML. Analysts at Zacks downgraded shares of Stemline Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Wednesday, November 12th. They now have a $17.30 price target on the stock.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

To get a free copy of the research report on Stemline Therapeutics (STML), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Instacart the Grocery Delivery Startup Raises $210 Million
Instacart the Grocery Delivery Startup Raises $210 Million
China Will Relax Regulations on Banks Renminbi Trading
China Will Relax Regulations on Banks Renminbi Trading
Subway in Safety Scandal in China over Food
Subway in Safety Scandal in China over Food
UPS and FedEx Make Improvements During Holiday Season
UPS and FedEx Make Improvements During Holiday Season
MasterCard Spending Report for Holidays Shows Weak Electronics
MasterCard Spending Report for Holidays Shows Weak Electronics
Gift Cards Have Become Hugely Popular, but Have Risks
Gift Cards Have Become Hugely Popular, but Have Risks


Leave a Reply

Advertisement
Advertisement
© 2006-2015 Leoncheng.